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Summary
Osteoarthritis is primarily characterized by areas of destruction of articular cartilage and by synovitis. Articular damage and synovitis are sec-
ondary to local increase of pro-inﬂammatory cytokines (interleukin-1b and tumor necrosis factor-a), enzymes with proteolytic activity (matrix
metalloproteinases), and enzymes with pro-inﬂammatory activity (cyclooxygenase-2 and nitric oxide synthase-2). Enhanced expression of
these proteins in chondrocytes and in synovial membrane appears associated to the activation and nuclear translocation of nuclear factor-
kB (NF-kB). Chondroitin sulfate (CS) prevents joint space narrowing and reduces joint swelling and effusion. To produce these effects, CS
elicits an anti-inﬂammatory effect at the chondral and synovial levels. CS and its disaccharides reduce NF-kB nuclear translocation, probably
by diminishing extracellular signal-regulated kinase1/2, p38mitogen-activated protein kinase and c-Jun N-terminal kinase activation. This re-
view discusses the evidence supporting that CS pleiotropic effects in chondrocytes and synoviocytes are primarily due to a common mech-
anism, e.g., the inhibition of NF-kB nuclear translocation.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis is characterized by focal areas of loss of
articular cartilage, with varying degrees of osteophyte
formation, subchondral bone change and synovitis1. The
pathophysiology of osteoarthrosis remains controversial. It
has been proposed that continuous use of the joint implies
multiple microtrauma to the articular cartilage and formation
of ﬁbronectin and extracellular matrix fragments (EMFs).
Fibronectin fragments (FN-f) contribute to cartilage destruc-
tion2 by binding to a5b1 integrin receptor of the chondrocyte
with the subsequent activation of protein kinase C (PKC),
proline-rich tyrosine kinase-2, extracellular signal-regulated
kinase1/2 (ERK1/2), p38mitogen-activated protein kinase
(p38MAPK) and c-Jun N-terminal kinase (JNK), that trigger
the nuclear translocation of activated protein-1 (AP-1) and
nuclear factor-kB (NF-kB), and enhanced expression of ma-
trix metalloproteinases (MMPs), MMP-3 and MMP-133.
MMPs will cleave the EMFs (Fig. 1).
In chondrocytes, increased expression of MMPs is
accompanied by an enhanced synthesis of pro-inﬂamma-
tory cytokines, essentially interleukin-1b (IL-1b) and tumor
necrosis factor-a (TNF-a), which will sustain the activation
of chondrocytes and moreover, will further promote the
formation of MMPs, aggrecanase, reactive oxygen interme-
diates, nitric oxide, and lipid-derivative inﬂammatory
mediators such as prostaglandins and leukotrienes; these
substances will enhance the catabolic activity of the chon-
drocytes and cause the destruction of the cartilage matrix.
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S14the synovial ﬂuid will activate macrophages, mastocytes
and synoviocytes in the synovial membrane originating
the synovitis. Activation of synovial cells will result in further
release of IL-1b, TNF-a and MMPs that will contribute to the
destruction of the cartilage matrix1,4e6 (Fig. 2).
There is clinical evidence showing that osteoarthritis and
synovitis are associated. Synovial abnormalities are detect-
able in 50% of patients with osteoarthrosis. Synovitis is
reﬂected by several of the signs and symptoms of osteoar-
thritis, such as swelling and effusion, redness, pain and
stiffness7. Moderate or large effusions and synovial thicken-
ing are more frequent among patients with knee pain than
those without pain, suggesting that these signs are associ-
ated with the pain of osteoarthritic knee; furthermore, the se-
verity of knee pain is associated with synovial thickening8. In
patients with osteoarthritis, changes in pain are closely asso-
ciated to the changes in synovitis but not to cartilage loss9.
The presence of synovitis at early stages of osteoarthritis
is associated with a more rapid and destructive progression
of the disease7. Finally, there is evidence that a subset of pa-
tients with osteoarthritic joint disease present synovitis and
synovial hyperplasia without cartilage damage and EMFs,
suggesting that in some patients, synovitis is a very early
or the initial event in the development of osteoarthritis10. In-
dependently of the sequence of events in the apparition of
osteoarthritis, e.g., cartilage damage or synovitis at the origin
of osteoarthritis, cartilage damage and synovitis are present
in a great proportion of patients, both contribute to the signs
and symptoms of osteoarthritis, and both should be the tar-
get of therapy.
Chondroitin sulfate (CS) in osteoarthritis,
clinical evidence
Randomized clinical trials have shown that CS reduces
pain and improves articular function11e13, reduces joint
swelling and effusion14, and prevents joint space narrowing
Fig. 1. Pro-inﬂammatory cytokines, EMFs and FN-f activate chondrocytes by increasing the phosphorylation of MAPK, such as ERK/MAPK,
p38MAPK and JNK, and nuclear translocation of NF-kB and AP-1. These transcription factors will induce the expression of cytokines, PLA2,
COX-2, MMPs, NOS-2, etc.
S15Osteoarthritis and Cartilage Supplement 3of the knee11,13 and ﬁngers15,16 more effectively than
placebo. According to these effects, CS has been classiﬁed
as a symptomatic slow acting drug in osteoarthritis
(SYSADOA) and a structure/disease modifying anti-osteo-
arthritis drug (S/DMOAD)11,15.Effect of CS on articular cartilage,
mechanism of action
The complex clinical response to CS may tentatively be
explained by the numerous effects elicited by CS. On the
one hand, the decrease in pain and swelling may be
explained by an anti-inﬂammatory effect of CS, probably
through diverse mechanisms such as diminishing the
expression of phospholipase A2 (PLA2)17, of cyclooxyFig. 2. Repetitive trauma on the articular cartilage leads to the production of
that will release pro-inﬂammatory cytokines and MMPs, that will maintaingenase-2 (COX-2), and the concentrations of prostaglandin
E2 (PGE2)
18,19. Moreover, in joints CS reduces the concen-
trations of pro-inﬂammatory cytokines, such as TNF-a20 and
IL-1b21, and systemic and joint concentrations of NO19,22
and of reactive oxygen species (ROS)20. On the other
hand, protection of the joint structure may be explained by
the fact that in chondrocytes, CS diminishes IL-1b-mediated
increase in MMP-218, MMP-318, MMP-918,19,21, MMP-
1318,19, and MMP-1418. Moreover, it has been documented
that hyaluronan and mixtures of low concentrations of CS
and glucosamine are able to prevent the release of MMP-
3 and MMP-13 triggered by FN-f23,24. Finally, in subchon-
dral bone, CS increases osteoprotegerin (OPG) and
reduces the expression of receptor activator of NF-kB
ligand (RANKL), effects that may result in the reduction of
the resorptive activity in subchondral bone25.debris of EMFs that will activate the chondrocyte and/or synoviocytes
local inﬂammation and cartilage and subchondral bone destruction.
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and abrogates the phosphorylation of p38MAPK induced
by IL-1b; as a consequence, CS reduces IL-1b-induced
NF-kB nuclear translocation. However, CS does not reduce
IL-1b-induced AP-1 nuclear translocation. On the other
hand, CS decreases nitroprusside-induced apoptosis of the
chondrocytes probably by preventing p38MAPKactivation26.
In chondrocytes, chondroitin disaccharides sulfated at posi-
tions4and/or6, (1-4)-O-(D-glucopyranosyluronicacid)e(1-3)-
O-(2-N-acetamido-2-deoxy-D-galactopyranosyl-4/6-sulfate)
(Ddi-4S, Ddi-6S and Ddi-4,6S) reduce IL-1b-induced NF-kB
nuclear translocation to a similar extent as CS, e.g., Ddi-4S,
Ddi-6S and Ddi-4,6S reduce NF-kB translocation by 11, 13
and 17%, respectively (P< 0.05, N¼ 9) (Fig. 3).
It has been widely documented in the chondrocytes that
IL-1b-induced increase in expression of MMP-327, MMP-
928, MMP-1327,29,30, COX-230,31, nitric oxide synthase-2
(NOS-2), IL-1b and TNF-a32 is mediated by the activation
and nuclear translocation of NF-kB and AP-1. Moreover,
there is evidence that the activation of PLA2 requires the
activation of p38MAPK and ERK1/231, and that the induc-
tion of RANKL expression requires the activation of
ERK1/2 and phosphatidylinositol 3-kinase/protein kinase B
(PI-3K/Akt) pathways33. Since the above mentioned effects
of IL-1b in the chondrocyte are mediated by the activation of
p38MAPK and of ERK1/2, and the nuclear translocation of
NF-kB, it is tempting to speculate that the pleiotropic effects
of CS are dependent, at least in part, by its ability to inhibit
p38MAPK and ERK1/2 phosphorylation and NF-kB nuclear
translocation.Effect of CS on the synovial membrane,
mechanism of action
Synovial tissue from patients with early osteoarthritis
shows activated ﬁbroblast-like synoviocytes (FLS),Fig. 3. Effect of CS disaccharides sulfated in positions 4 and/or 6
(Ddi-4S, Ddi-6S Ddi-4,6S) on Il-1b- induced NF-B nuclear
translocation. 200 mg/ml of the disaccharides were incubated with
chondrocytes of rabbits and 24 h later, IL-1b (5 ng/ml) was added,
and the chondrocytes were incubated for an additional 48 h when
the nuclear translocation of NF-kB was assessed by immunoﬂuo-
rescence as described elsewhere26. *,&P< 0.05 compared with
control and IL-1b, respectively.macrophages, T lymphocytes, and mast cells inﬁltration34.
FLS release IL-1b, IL-6, IL-8, MMP-1, MMP-2, MMP-3,
MMP-13, MMP-14, MMP-16, tissue inhibitor of metalloprotei-
nases-1 (TIMP-1), RANKL, transforming growth factor-
b (TGF-b), vascular endothelial growth factor (VEGF), and
ﬁbroblast growth factor (FGF)4.
There is evidence supporting that the role of NF-kB in the
development of synovitis appears pivotal. In FLS, the pro-
duction of IL-1b, IL-6, IL-8, and MMP-1, MMP-3, requires
the activation and nuclear translocation of NF-kB35,36.
Moreover, the activation of NF-kB increases FLS prolifera-
tion and changes the phenotype of these cells to highly
invasive FLS with great motility and ability to secrete
cytokines and MMP-1337. Inhibition of the IkB kinase
(IKK) complex impedes the phosphorylation of the inhibitor
of kB (IkBa) and as a consequence, prevents NF-kB activa-
tion. In synovial macrophages, inhibition of IKK diminishes
IL-1b-induced production of IL-6; moreover, in rats with
adjuvant-induced arthritis, intra-articular injection of a spe-
ciﬁc IKK-b inhibitor reduces arthritis activity and bone
destruction; synovial inﬂammation was also decreased as
documented by the reduction in synovial cellularity, TNF-
a, IL-1-b concentrations, and reduction of the volume of
the paw38. The role of NF-kB in the initiation of synovitis
was further supported by administering in the articulation
of the rat with adjuvant-induced arthritis a dominant-nega-
tive form of IKK-b that reduced synovial cellularity by
50%, and diminished synovial concentrations of IL-1b,
TNF-a and MMP-339. These results provide evidence that
activation and nuclear translocation of NF-kB is an impor-
tant step in the development of synovitis.
There is little information about the effect of osteoarthri-
tis treatment with CS on synovitis manifestations, e.g.,
joint swelling and effusion. The multicenter, double-blind,
placebo- and celecoxib-controlled Glucosamine/chondroi-
tin Arthritis Intervention Trial (GAIT) assessed the effect
of CS and glucosamine alone or in combination on joint
swelling and/or effusion in 1583 patients with mild to se-
vere knee osteoarthritis14. The patients received
1200 mg of CS, or 1500 mg of glucosamine or both CS
and glucosamine, or 200 mg of celecoxib or placebo, daily
for 24 weeks. The trial demonstrates that CS diminished
the percentage of patients with signs of synovitis (joint
swelling and effusion) from 28.3% at baseline to 12.4%
at the end of 24 weeks of treatment (P¼ 0.01, N¼ 307).
It is of interest that the beneﬁcial effect of CS (P¼ 0.02,
N¼ 248) was observed in the patients with mild pain
(Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) pain scores 125e300). In patients with
moderate to severe pain (WOMAC pain scores
301e400) receiving CS, the percentage of patients with
swelling and/or effusion tended to decrease from 30.0%
at baseline to 14.9% (P¼ 0.3, N¼ 67) at the end of
follow-up.
Further supporting that CS reduces the signs and symp-
toms of synovitis, a study showed that intra-articular injec-
tion of hyaluronate, a glycosaminoglycan with a molecular
weight of 8.4 105, to patients with rheumatoid arthritis im-
proves local clinical symptoms, decreases synovial ﬂuid,
reduces PGE2 concentrations and diminishes pain
40.
Several animal studies demonstrate that CS reduces the
signs and symptoms of synovitis. In DBA/1J mice with
a type II collagen-induced arthritis, treated for 9 weeks
with various dosages of CS, the inﬁltration of inﬂammatory
cells, granulated tissue formation, proliferation of synovial
lining cells, paw edema and destruction of articular cartilage
were partially prevented by treatment with 1000 mg/kg/day
Fig. 4. Diagram depicting the potential sites of effect of CS and/or its disaccharides. Local microtraumas produce EMFs and FN-f that activate
chondrocytes by increasing the nuclear translocation of NF-kB in the chondrocytes, synovial macrophages and synoviocytes. NF-kB has
a key role in the pro-inﬂammatory activation of chondrocytes, and synovial macrophages, mast cells, T-cells and synoviocytes and in the
release of cytokines and MMPs, that will sustain cartilage and subchondral bone destruction.
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induced by injecting the right radiocarpal joint with chymo-
papain, prior treatment with CS reduces the extend of syno-
vitis42. In rabbits with experimental osteoarthritis, intra-
articular administration of N-acetylglucosamine elicited an
anti-inﬂammatory effect and suppressed the synovitis43.
All these studies strongly support that in animal models
and in humans, glycosaminoglycans reduce the signs and
symptoms of synovitis. The mechanism of action underly-
ing the reduction of synovitis by CS and other glycosami-
noglycans remains incompletely characterized. It has
been reported that CS disaccharide Ddi-6S reduces IL-
1b-induced nuclear translocation of NF-kB by 67% in syn-
oviocytes44. This observation is in agreement with the ef-
fect of CS and its Ddi-4S and Ddi-6S disaccharides in
chondrocytes, e.g., they reduce NF-kB nuclear transloca-
tion. Since oral CS increases plasma concentrations of
Ddi-4S and Ddi-6S45, it is conceivable that in humans,
the decrease in synovitis signs produced by CS may be
explained, at least in part, by the reduction in NF-kB nu-
clear translocation in synoviocytes and macrophages,
with the subsequent diminution of activation of these cells
and decrease in synovitis.
In summary, CS and/or the sulfated disaccharides ap-
pear to elicit an anti-inﬂammatory effect at the synovial
membrane and chondrocytes levels. Possibly, CS and/or
disaccharides reduce the inﬂammatory reaction by dimin-
ishing NF-kB nuclear translocation (Fig. 4). In the chon-
drocytes, this effect is mediated by the inhibition of
p38MAPK phosphorylation and to a minor degree ERK1/
2 phosphorylation. Indeed, further studies are required to
better characterize the precise mechanism of action un-
derlying CS-induced improvement of synovitis.Conﬂict of interest
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